Nanobiotix Appoints Its Manufacturing Partner, CordenPharma: Another Step Towards Commercialization

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma as its manufacturing partner. The opening of a new manufacturing line and the scaling up of production is an important step in NBTXR3s route to commercialization.

The new manufacturing line, located in France, will increase the amount of NBTXR3 product available. With an anticipated award of a CE mark in 2016, the Company is preparing to scale-up production further to meet the needs of future commercialization. Furthermore, Nanobiotix is anticipating future demand from clinical trials in the coming years in Europe and in the United States.

CordenPharma is an international full service CMO (contract manufacturing organization) which provides specialized technologies for the development and manufacture of health products. The company is recognized by EMA and FDA thanks to its eight cGMP facilities across Europe and the United States and works with both pharma and biotech companies. Its facilities are regularly inspected by the regulatory authorities (FDA and EMA) and have a good track record.

Laurent Lvy, Chief Executive Officer at Nanobiotix, commented: Finding the right manufacturing partner is essential, since ensuring quality and sufficient levels of supply is fundamental for meeting the market demands and the growth of the Company.

Yves Michon, Prsident Synkem - CordenPharma said: Nanobiotixs product, NBTXR3 is a fascinating product not only with respect to its properties, but also in its manufacture. We are working closely with Nanobiotix to ensure a seamless process and manage the scale-up of the product.

NBTXR3 is Nanobiotixs lead product in the NanoXray portfolio. The product comprises Hafnium Oxide nanoparticles which can be injected directly into tumor. With the application of radiotherapy, these nanoparticles absorb X-rays have the potential to significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues. NBTXR3 has the potential to cause a paradigm shift in cancer therapy with significant clinical benefit for patients.

In November 2014, Nanobiotix announced its global clinical development plan. In addition to Soft Tissue Sarcoma and Head and Neck cancer, the plan now includes metastatic liver cancer, hepatocellular carcinomas and prostate cancer. In the second half of 2015, the liver cancers and high risk prostate cancer programs are anticipated to enter the clinical stage.

About NANOBIOTIX: http://www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotixs lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

See the rest here:
Nanobiotix Appoints Its Manufacturing Partner, CordenPharma: Another Step Towards Commercialization

SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases – Video


SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases
Speaker: Prof. Dr. med. Patrick Couvreur, Centre d #39;tudes Pharmaceutiques (CNRS), Paris (F) "European Research Council -Related Talks on Nanomedicine and Drug Delivery" Chair: Dr. Twan ...

By: TAUVOD

See original here:
SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases - Video

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations

UCLA bioengineers develop platform that offers personalized approach to treatment

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. And one of their greatest challenges is determining which ratio and combination -- from the large number of medications available -- is best for each individual patient.

Dr. Dean Ho, a professor of oral biology and medicine at the UCLA School of Dentistry, and Dr. Chih-Ming Ho, a professor of mechanical engineering at the UCLA Henry Samueli School of Engineering and Applied Science, have developed a revolutionary approach that brings together traditional drugs and nanotechnology-enhanced medications to create safer and more effective treatments. Their results are published in the peer-reviewed journal ACS Nano.

Chih-Ming Ho, the paper's co-corresponding author, and his team have developed a powerful new tool to address drug resistance and dosing challenges in cancer patients. The tool, Feedback System Control.II, or FSC.II, considers drug efficacy tests and analyzes the physical traits of cells and other biological systems to create personalized "maps" that show the most effective and safest drug-dose combinations.

Currently, doctors use people's genetic information to identify the best possible combination therapies, which can make treatment difficult or impossible when the genes in the cancer cells mutate. The new technique does not rely on genetic information, which makes it possible to quickly modify treatments when mutations arise: the drug that no longer functions can be replaced, and FSC.II can immediately recommend a new combination.

"Drug combinations are conventionally designed using dose escalation," said Dean Ho, a co-corresponding author of the study and the co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the School of Dentistry. "Until now, there hasn't been a systematic way to even know where the optimal drug combination could be found, and the possible drug-dose combinations are nearly infinite. FSC.II circumvents all of these issues and identifies the best treatment strategy."

The researchers demonstrated that combinations identified by FSC.II could treat multiple lines of breast cancer that had varying levels of drug resistance. They evaluated the commonly used cancer drugs doxorubicin, mitoxantrone, bleomycin and paclitaxel, all of which can be rendered ineffective when cancer cells eject them before they have had a chance to function.

The researchers also studied the use of nanodiamonds to make combination treatments even more effective. Nanodiamonds -- byproducts of conventional mining and refining operations -- have versatile characteristics that allow drugs to be tightly bound to their surface, making it much harder for cancer cells to eliminate them and allowing toxic drugs to be administered over a longer period of time.

The use of nanodiamonds to treat cancer was pioneered by Dean Ho, a professor of bioengineering and member of the UCLA Jonsson Comprehensive Cancer Center and the California NanoSystems Institute.

"This study has the capacity to turn drug development, nano or non-nano, upside-down," he said. "Even though FSC.II now enables us to rapidly identify optimized drug combinations, it's not just about the speed of discovering new combinations. It's the systematic way that we can control and optimize different therapeutic outcomes to design the most effective medicines possible."

Continue reading here:
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations

How to introduce Nanomedicine Products and bring their Impact to the Market? – Video


How to introduce Nanomedicine Products and bring their Impact to the Market?
Speaker: Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

See the rest here:
How to introduce Nanomedicine Products and bring their Impact to the Market? - Video

Nanomedicine characterization at NCI’s Nanotechnology Characterization Lab (NCL) – Video


Nanomedicine characterization at NCI #39;s Nanotechnology Characterization Lab (NCL)
Speaker: Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute (USA) CLINAM 7/ 2014, 7th Conference and Exhibi...

By: TAUVOD

Go here to see the original:
Nanomedicine characterization at NCI's Nanotechnology Characterization Lab (NCL) - Video

Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development – Video


Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development
Speaker: Dr. Cristianne JF Rijcken, PharmD, CEO, Cristal Delivery B.V., Maastricht (NL) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

Go here to see the original:
Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development - Video

Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com

London, UK (PRWEB) March 05, 2015

The emergence of nanotechnology has greatly impacted the clinical therapeutics landscape over the past decade. The pharmaceutical world has witnessed advancements in biocompatible nanoscale carriers for drug delivery in the form of liposomes and polymeric nanoparticles that are capable of delivering manifold drugs with more safety and efficiency. In the area of cancer therapeutics, the nanoparticles could perhaps rely greatly upon the enhanced permeability and retention (EPR) effect induced by leaky tumour vasculatures for a better accumulation of drugs at the tumour sites. Due to these benefits, the therapeutic nanoparticles in this respect have grown into a very promising field with the potential to successfully take the place of traditional chemotherapy.

The development of nanoparticle drug delivery systems for the treatment of cancer is set to become a lucrative field in the years to come. The protein polymers from natural sources emerge as up-and-coming materials for building the nanocarrier systems. The commercial success of albumin-based nanoparticles has also generated great interest in other proteins. With the rational design of protein nanoparticles on the grounds of their behaviours in the tumour microenvironment and based on the cell biology of cancer, enhanced cancer treatment efficacy and safety can be achieved.

Topical report Cancer Nanomedicine Market & Pipeline Insight 2015 worked out by Kuick Research is now available at MarketPublishers.com.

Report Details:

Title: Cancer Nanomedicine Market & Pipeline Insight 2015 Published: February, 2015 Pages: 220 Price: US$ 2,000.00 http://marketpublishers.com/report/diagnostics-diseases/cancer/cancer-nanomedicine-market-pipeline-insight-2015.html

The report offers an essential guide to the worldwide cancer nanomedicine marketplace. It provides deep insights into the role of nanomedicine in cancer therapies, contains a detailed classification of cancer nanoparticles drug delivery systems, looks at the mechanism of tumour nanomedicine treatment. The study presents a deep overview of the cancer nanomedicine clinical development pipeline, looking at it based on indication, stage and company. It reviews the 79 candidates in clinical development, the 8 marketed cancer nanomedicine drugs. The competitive landscape is canvassed as well including a discussion of the 11 leading companies. The report casts light on the market dynamics covering key drivers and commercialisation challenges, besides speculating on the future prospects of the market.

Companies reviewed comprise: Abraxis BioScience, Alnylam Pharmaceuticals, Access Pharmaceuticals, Bind Biosciences, Samyang, Arrowhead Research, Epeius Biotechnologies, Nanobiotix, Nippon Kayaku, NanoCarrier, and Takeda Pharmaceutical.

Report Highlights:

More topical studies by the publisher can be found at Kuick Research page.

The rest is here:
Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com

Center for Drug Delivery and Nanomedicine (CDDN

The need for the discovery and development of innovative technologies to improve the delivery of therapeutic and diagnostic agents in the body is widely recognized. The next generation therapies must be able to deliver drugs, therapeutic proteins and recombinant DNA to focal areas of disease or to tumors to maximize clinical benefit while limiting untoward side effects. The use of nanoscale technologies to design novel drug delivery systems and devices is a rapidly developing area of biomedical research that promises breakthrough advances in therapeutics and diagnostics.

Center for Drug Delivery and Nanomedicine (CDDN) serves to unify existing diverse technical and scientific expertise in biomedical and material science research at the University of Nebraska thereby creating a world class interdisciplinary drug delivery and nanomedicine program. This is realized by integrating established expertise in drug delivery, gene therapy, neuroscience, pathology, immunology, pharmacology, vaccine therapy, cancer biology, polymer science and nanotechnology at the University of Nebraska Medical Center (UNMC), the University of Nebraska at Lincoln (UNL) and Creighton University.

CDDNs vision is to improve health by enhancing the efficacy and safety of new and existing therapeutic agents, diagnostic agents and genes through the discovery and application of innovative methods of drug delivery and nanotechnology. CDDNs mission is to discover and apply knowledge to design, develop and evaluate novel approaches to improve the delivery of therapeutic agents, diagnostic agents and genes.

The COBRE Nebraska Center for Nanomedicine is supported by the National Institute of General Medical Science(NIGMS) grant 2P20 GM103480-07.

Link:
Center for Drug Delivery and Nanomedicine (CDDN

Professor Robert Langer joins Nanobiotix as Scientific Advisor

Laurent Levy, CEO of Nanobiotix, commented: "We really appreciate that Professor Langer joined us as a Scientific Advisor. Professor Langer is a globally acknowledged nanomedicine expert and serial business innovator, and his involvement will be an asset for our technologies, our development and expansion beyond cancer".

Professor Langer presides over the largest academic biomedical engineering laboratory in the world. His laboratory is centered in the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. His team has more than 100 researchers including chemists, biologists, materials science engineers and computer scientists.

He is also a Principle Investigator at the MIT-Harvard Center for Cancer Nanotechnology Excellence, one of eight Centers of Cancer Nanotechnology Excellence awarded by The National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Beyond his extensive involvement and leadership in MIT's scientific community, Professor Langer's research has spawned a vast array of innovative and disruptive technologies. He holds over 1,000 patents in diverse areas of biomedical technology and has been involved in the launch or acceleration of numerous biotech companies including BIND Therapeutics, Enzytech and Pervasis as examples.

Professor Langer said: "Radical and disruptive technologies are always required. An interdisciplinary approach to research and development is critical to ensure that these technologies are developed to their fullest potential. I see NanoXray technology as one of the technologies that could make a significant difference to disease treatment. Nanobiotix has very exciting and innovative projects and I look forward to working with the Team".

In September 2014, Nanobiotix opened its US affiliate in the Boston Life Science hub, in Cambridge MA. The location provides access to a critical mass of academic and medical institutions as well as biopharmaceutical industries, and will ensure access to the research community and clinical expertise in the US.

About NANOBIOTIX: http://www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September, 2014.

Visit link:
Professor Robert Langer joins Nanobiotix as Scientific Advisor